by Arif Gunawan S & Bambang P. Jatmiko
Bisnis Indonesia
PT Kalbe Farma Tbk, a publicly-listed pharmaceutical company, plans to expand its energy drink product, Extra Joss, to Vietnam market after a successful expansion Philippine market.
Corporate Secretary of PT Kalbe Farma Vidjongtius confirmed that the company expects the expansion plan into the neighboring countries to be realized in the next year. Referring to the expansion in Philippine, the company allocates an investment fund of about US$5 million or IDR50 billion.
“The expansion will be relatively same as in the Philippine's as we will involve a local partner to market the product in Vietnam,” he said after attending an Investor Day, this morning.
Until now, as he added, the company is still seeking for potential local partners in Vietnam.
In the first half 2010, the listed pharmaceutical company posted IDR4.71 trillion net sales or rose by 11.6%, compared to that of in the same period last year as much as IDR4.22 billion.
The net income climbed 43.55% from IDR398.71 billion to IDR572.34 billion. Consequently, its net income margin jumped by 28.62% to 12.16%.
“The good result confirms the company's strategies, in terms of operation and financial management, have delivered optimum outcome
Bisnis Indonesia
PT Kalbe Farma Tbk, a publicly-listed pharmaceutical company, plans to expand its energy drink product, Extra Joss, to Vietnam market after a successful expansion Philippine market.
Corporate Secretary of PT Kalbe Farma Vidjongtius confirmed that the company expects the expansion plan into the neighboring countries to be realized in the next year. Referring to the expansion in Philippine, the company allocates an investment fund of about US$5 million or IDR50 billion.
“The expansion will be relatively same as in the Philippine's as we will involve a local partner to market the product in Vietnam,” he said after attending an Investor Day, this morning.
Until now, as he added, the company is still seeking for potential local partners in Vietnam.
In the first half 2010, the listed pharmaceutical company posted IDR4.71 trillion net sales or rose by 11.6%, compared to that of in the same period last year as much as IDR4.22 billion.
The net income climbed 43.55% from IDR398.71 billion to IDR572.34 billion. Consequently, its net income margin jumped by 28.62% to 12.16%.
“The good result confirms the company's strategies, in terms of operation and financial management, have delivered optimum outcome
Comments